Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | GAA | P10253 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | GFER | P55789 | 4/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dioxane SCHEMBL25199508 | 0.93 | MAPT (0.52) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL15650643 | 0.88 | MAPT (0.50) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL16330372 | 0.88 | MAPT (0.50) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL24418020 | 0.83 | ALDH1A1 (0.46) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL17264101 | 0.83 | MAPT (0.59) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL6637762 | 0.82 | EED (0.50) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL10142446 | 0.81 | USP2 (0.59) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL3441371 | 0.81 | MAPT (0.57) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL14320362 | 0.81 | MAPT (0.61) | MAPTALDH1A1GAAKDM4EKMT2A | |
| SCHEMBL10147276 | 0.80 | USP2 (0.54) | MAPTALDH1A1GAAKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768862-A | Indole pyrazole compound as well as preparation method and application thereof | 郑州大学 | 2023-09-19 | — | — | CN | claimed |
| US-6890362-B2 | Oxidation dyeing composition for keratinous fibers and dyeing method using same | L'OREAL, S.A. (FR) | 2005-05-10 | — | — | US | claimed |
| US-20040088798-A1 | Oxidation dyeing composition for keratinous fibres and dyeing method using same | LANG GERARD (FR) | 2004-05-13 | — | — | US | claimed |
| US-20030167579-A1 | Oxidation dyeing composition for keratinous fibres and dyeing method using same | L'OREAL S.A. (FR) | 2003-09-11 | — | — | US | claimed |
| US-20030159221-A1 | Oxidation dyeing composition for keratinous fibres with a particular paraphenylene-diamine derivative and a particular direct dyeing agent | L'OREAL S.A. (FR) | 2003-08-28 | — | — | US | claimed |
| US-20030028977-A1 | Oxidation dyeing composition for keratinous fibres and dyeing method using same | L'OREAL S.A. (FR) | 2003-02-13 | — | — | US | claimed |
| US-20030009835-A1 | Oxidation dyeing composition for keratinous fibres and dyeing method using same | L'OREAL S.A. (FR) | 2003-01-16 | — | — | US | claimed |
| EP-1263398-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2002-12-11 | — | — | EP | claimed |
| EP-1263399-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2002-12-11 | — | — | EP | claimed |
| EP-1263397-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES WITH A PARTICULAR PARAPHENYLENEDIAMINE DERIVATIVE AND A PARTICULAR DIRECT DYEING AGENT | L'OREAL (FR) | 2002-12-11 | — | — | EP | claimed |
| CN-1372457-A | Oxidation dyeing composition for kevatinous fibers and dyeing method using same | OREAL (FR) | 2002-10-02 | — | — | CN | claimed |
| CN-1372458-A | Oxidation dyeing composition for keratinous fibres and dyeing method using said composition | OREAL (FR) | 2002-10-02 | — | — | CN | claimed |
| EP-1181005-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2002-02-27 | — | — | EP | claimed |
| EP-1181004-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2002-02-27 | — | — | EP | claimed |
| WO-2001066071-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2001-09-13 | — | — | WO | claimed |
| WO-2001066068-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES WITH A PARTICULAR PARAPHENYLENEDIAMINE DERIVATIVE AND A PARTICULAR DIRECT DYEING AGENT | L'OREAL (FR) | 2001-09-13 | — | — | WO | claimed |
| WO-2001066072-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2001-09-13 | — | — | WO | claimed |
| WO-2001066069-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2001-09-13 | — | — | WO | claimed |
| WO-2001066070-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2001-09-13 | — | — | WO | claimed |
| CN-119431239-A | Compounds, pharmaceutical compositions, kits and uses thereof | 密执安大学评议会 | 2025-02-14 | — | — | CN | disclosed |
| CN-113710241-B | Substituted bicyclic and tetracyclic quinones and related methods of use | 密执安大学评议会 | 2024-11-15 | — | — | CN | disclosed |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-31 | — | — | US | disclosed |
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-03 | — | — | US | disclosed |
| EP-4427812-A2 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE | The Regents of the University of Michigan (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-115151252-B | Iron death inhibitor-diarylamine acetamides | 维泰瑞隆有限公司 | 2024-08-27 | — | — | CN | disclosed |
| EP-3934634-B1 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND RELATED METHODS OF USE | UNIV MICHIGAN REGENTS (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4384493-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2024-06-19 | — | — | EP | disclosed |
| CN-118076581-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117999259-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-113646899-B | n-type semiconductor element, method for manufacturing n-type semiconductor element, wireless communication device, and commodity tag | 东丽株式会社 | 2024-03-12 | — | — | CN | disclosed |
| CN-116768862-A | Indole pyrazole compound as well as preparation method and application thereof | 郑州大学 | 2023-09-19 | — | — | CN | disclosed |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2023016447-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016447-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-02-16 | — | — | WO | disclosed |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
| US-11561440-B2 | Photoalignment composition for the stabilization of the pre-tilt angle in liquid crystal layers | Rolic Technologies AG (CH) | 2023-01-24 | — | — | US | disclosed |
| WO-2023280296-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023280296-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-01-12 | — | — | WO | disclosed |
| US-20220273659-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO OPERATING COMPANY LLC | 2022-09-01 | — | — | US | disclosed |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220162167-A1 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND USE THEREOF AS ANTI-CANCER AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-05-26 | — | — | US | disclosed |
| EP-3993802-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114340634-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-02-24 | — | — | US | disclosed |
| US-11040978-B2 | Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-06-22 | — | — | US | disclosed |
| WO-2021003314-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021003314-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| EP-3694509-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Nuvation Bio Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2020140054-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020140055-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020140053-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020140052-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2020085450-A1 | LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2020-04-30 | — | — | WO | disclosed |
| US-20200073181-A1 | NEW PHOTOALIGNMENT COMPOSITION FOR THE STABILIZATION OF THE PRE-TILT ANGLE IN LIQUID CRYSTAL LAYERS | Rolic Technologies AG (CH) | 2020-03-05 | — | — | US | disclosed |
| US-10557085-B2 | Photoalignment composition | ROLIC AG (CH) | 2020-02-11 | — | — | US | disclosed |
| US-20190315755-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2019-10-17 | — | — | US | disclosed |
| US-20190211020-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-07-11 | — | — | US | disclosed |
| US-10280168-B2 | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-05-07 | — | — | US | disclosed |
| WO-2019074981-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GiraFpharma LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| US-20180208600-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-07-26 | — | — | US | disclosed |
| EP-3321268-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | Agency For Science, Technology And Research (SG) | 2018-05-16 | — | — | EP | disclosed |
| US-20180079961-A1 | PHOTOALIGNMENT COMPOSITION | ROLIC AG (CH) | 2018-03-22 | — | — | US | disclosed |
| US-9908886-B2 | Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-03-06 | — | — | US | disclosed |
| US-9765235-B2 | Photoaligning material | ROLIC AG (CH) | 2017-09-19 | — | — | US | disclosed |
| EP-2831079-B1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2017-08-16 | — | — | EP | disclosed |
| US-20170184923-A1 | LIQUID CRYSTAL DISPLAY ELEMENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL ALIGNMENT TREATMENT AGENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-06-29 | — | — | US | disclosed |
| US-9556148-B2 | N-cyanomethylamides as inhibitors of janus kinase | CADILA HEALTHCARE LIMITED (IN) | 2017-01-31 | — | — | US | disclosed |
| US-9421205-B2 | FAK inhibitors | Cancer Therapeutics CRC Pty Ltd. (AU) | 2016-08-23 | — | — | US | disclosed |
| US-20160176849-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LIMITED (IN) | 2016-06-23 | — | — | US | disclosed |
| CN-105503775-A | Diamine monomer with triphenylamine structure containing p-substituted cyclic amine, preparation method and application of diamine monomer | UNIV JILIN | 2016-04-20 | — | — | CN | disclosed |
| US-9249163-B2 | PDE10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV. (BE) | 2016-02-02 | — | — | US | disclosed |
| US-9193736-B2 | PDE 10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2015-11-24 | — | — | US | disclosed |
| WO-2015128698-A1 | SUBSTITUTED HETEROCYCLIC AMINE DERIVATIVES AS MULTIKINASE INHIBITORS FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2015-09-03 | — | — | WO | disclosed |
| US-20150231135-A1 | FAK INHIBITORS | Cancer Therapeutics CRC Pty Ltd. (AU) | 2015-08-20 | — | — | US | disclosed |
| US-9012461-B2 | FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-04-21 | — | — | US | disclosed |
| WO-2015022980-A1 | LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学工業株式会社 (JP) | 2015-02-19 | — | — | WO | disclosed |
| US-20150038506-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-02-05 | — | — | US | disclosed |
| EP-2831079-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | Agency For Science, Technology And Research (SG) | 2015-02-04 | — | — | EP | disclosed |
| WO-2015002291-A1 | POLYMER COMPOSITION AND LIQUID CRYSTAL ALIGNMENT FILM FOR IN-PLANE-SWITCHING-TYPE LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学工業株式会社 (JP) | 2015-01-08 | — | — | WO | disclosed |
| US-20140371199-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-12-18 | — | — | US | disclosed |
| US-20140364413-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
| WO-2014119682-A1 | LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学工業株式会社 (JP) | 2014-08-07 | — | — | WO | disclosed |
| US-20140142094-A1 | KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2731953-A1 | TRICYCLIC INHIBITORS OF KINASES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Abbvie Inc. (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8716297-B2 | Chemical entities to be used for Wee1 inhibition for the treatment of cancer | ABBVIE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2702064-A1 | KINASE INHIBITORS | Icahn School of Medicine at Mount Sinai (US) | 2014-03-05 | — | — | EP | disclosed |
| CN-103619854-A | Kinase inhibitors | SINAI SCHOOL MEDICINE | 2014-03-05 | — | — | CN | disclosed |
| WO-2013147711-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013081064-A1 | LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME | 日産化学工業株式会社 (JP) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013012681-A1 | TRICYCLIC INHIBITORS OF KINASES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20130017194-A1 | FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-17 | — | — | US | disclosed |
| US-20130018045-A1 | New Chemical Entities To Be Used For Wee1 Inhibition For The Treatment Of Cancer | ABBOTT LABORATORIES (US) | 2013-01-17 | — | — | US | disclosed |
| WO-2012149567-A1 | KINASE INHIBITORS | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012149567-A1 | KINASE INHIBITORS | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012002501-A1 | LIQUID CRYSTAL ALIGNMENT TREATMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT EQUIPPED WITH THE LIQUID CRYSTAL ALIGNMENT FILM | 日産化学工業株式会社 (JP) | 2012-01-05 | — | — | WO | disclosed |
| US-6890362-B2 | Oxidation dyeing composition for keratinous fibers and dyeing method using same | L'OREAL, S.A. (FR) | 2005-05-10 | — | — | US | disclosed |
| CN-1555260-A | Aminoalkyl-substituted aromatic bicyclic compounds, process for their preparation and their use as pharmaceuticals | ���ĵ�˹ҩ��¹�����˾ | 2004-12-15 | — | — | CN | disclosed |
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
| US-20040088798-A1 | Oxidation dyeing composition for keratinous fibres and dyeing method using same | LANG GERARD (FR) | 2004-05-13 | — | — | US | disclosed |
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-11-13 | — | — | US | disclosed |
| US-20030167579-A1 | Oxidation dyeing composition for keratinous fibres and dyeing method using same | L'OREAL S.A. (FR) | 2003-09-11 | — | — | US | disclosed |
| US-20030159221-A1 | Oxidation dyeing composition for keratinous fibres with a particular paraphenylene-diamine derivative and a particular direct dyeing agent | L'OREAL S.A. (FR) | 2003-08-28 | — | — | US | disclosed |
| US-20030028977-A1 | Oxidation dyeing composition for keratinous fibres and dyeing method using same | L'OREAL S.A. (FR) | 2003-02-13 | — | — | US | disclosed |
| US-20030009835-A1 | Oxidation dyeing composition for keratinous fibres and dyeing method using same | L'OREAL S.A. (FR) | 2003-01-16 | — | — | US | disclosed |
| EP-1263398-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2002-12-11 | — | — | EP | disclosed |
| EP-1263399-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2002-12-11 | — | — | EP | disclosed |
| EP-1263397-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES WITH A PARTICULAR PARAPHENYLENEDIAMINE DERIVATIVE AND A PARTICULAR DIRECT DYEING AGENT | L'OREAL (FR) | 2002-12-11 | — | — | EP | disclosed |
| EP-1181004-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2002-02-27 | — | — | EP | disclosed |
| EP-1181005-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2002-02-27 | — | — | EP | disclosed |
| WO-2001066068-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES WITH A PARTICULAR PARAPHENYLENEDIAMINE DERIVATIVE AND A PARTICULAR DIRECT DYEING AGENT | L'OREAL (FR) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001066068-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES WITH A PARTICULAR PARAPHENYLENEDIAMINE DERIVATIVE AND A PARTICULAR DIRECT DYEING AGENT | L'OREAL (FR) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001066070-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001066072-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001066069-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001066071-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES AND DYEING METHOD USING SAME | L'OREAL (FR) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (35 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018045-A1 | New Chemical Entities To Be Used For Wee1 Inhibition For The Treatment Of Cancer | WEE1, WEE2, CCNE1 | MAPT 3918/4885ALDH1A1 1453/4885GAA 1792/4885 |
| US-10280168-B2 | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof | MAPKAPK2, NEK2, MKNK2 | MAPT 674/4885ALDH1A1 3056/4885GAA 1854/4885 |
| US-20030159221-A1 | Oxidation dyeing composition for keratinous fibres with a particular paraphenylene-diamine derivative and a particular direct dyeing agent | KRT18, CDC73, DAO | MAPT 1020/4885ALDH1A1 383/4885GAA 4224/4885 |
| US-20140364413-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | PDE2A, PDE3B, PDE3A | MAPT 4646/4885ALDH1A1 381/4885GAA 326/4885 |
| US-20130017194-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | MAPT 2189/4885ALDH1A1 3192/4885GAA 4663/4885 |
| US-20150038506-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, NEK2, MKNK2 | MAPT 680/4885ALDH1A1 3056/4885GAA 1854/4885 |
| US-20190315755-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, MKNK2, MAP4K2 | MAPT 525/4885ALDH1A1 4308/4885GAA 2909/4885 |
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | MAPT 4445/4885ALDH1A1 2869/4885GAA 1874/4885 |
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MAPT 3514/4885ALDH1A1 404/4885GAA 1687/4885 |
| US-20140142094-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K2 | MAPT 1788/4885ALDH1A1 2958/4885GAA 1171/4885 |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | MAPT 3636/4885ALDH1A1 4227/4885GAA 3009/4885 |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | MAPT 2954/4885ALDH1A1 1441/4885GAA 771/4885 |
| US-20030028977-A1 | Oxidation dyeing composition for keratinous fibres and dyeing method using same | KRT18, NDUFB5, NDUFB4 | MAPT 805/4885ALDH1A1 139/4885GAA 4382/4885 |
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | MAPT 3110/4885ALDH1A1 1306/4885GAA 861/4885 |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MAPT 3514/4885ALDH1A1 404/4885GAA 1687/4885 |
| US-20160176849-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | JAK1, JAK3, JAK2 | MAPT 3232/4885ALDH1A1 2346/4885GAA 1302/4885 |
| US-20230065740-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | MAPT 3636/4885ALDH1A1 4227/4885GAA 3009/4885 |
| US-20030167579-A1 | Oxidation dyeing composition for keratinous fibres and dyeing method using same | KRT18, PPOX, COXFA4L2 | MAPT 878/4885ALDH1A1 361/4885GAA 3612/4885 |
| US-20190211020-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, NEK2, MKNK2 | MAPT 680/4885ALDH1A1 3056/4885GAA 1854/4885 |
| US-20220273659-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | MAPT 3156/4885ALDH1A1 2992/4885GAA 2341/4885 |
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MAPT 3514/4885ALDH1A1 404/4885GAA 1687/4885 |
| US-20040088798-A1 | Oxidation dyeing composition for keratinous fibres and dyeing method using same | KRT18, OAT, ACOX1 | MAPT 1555/4885ALDH1A1 477/4885GAA 4428/4885 |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | MAPT 3636/4885ALDH1A1 4227/4885GAA 3009/4885 |
| US-20030009835-A1 | Oxidation dyeing composition for keratinous fibres and dyeing method using same | KRT18, PPOX, NDUFB5 | MAPT 540/4885ALDH1A1 321/4885GAA 4105/4885 |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MAPT 3514/4885ALDH1A1 404/4885GAA 1687/4885 |
| US-20180208600-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, MKNK2, MAP4K2 | MAPT 525/4885ALDH1A1 4308/4885GAA 2909/4885 |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | PDE2A, PDE3B, PDE3A | MAPT 4646/4885ALDH1A1 381/4885GAA 326/4885 |
| US-20220162167-A1 | SUBSTITUTED BICYCLIC AND TETRACYCLIC QUINONES AND USE THEREOF AS ANTI-CANCER AGENTS | MCL1, NQO1, GLS | MAPT 2167/4885ALDH1A1 910/4885GAA 2416/4885 |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, CCNE1 | MAPT 4642/4885ALDH1A1 1113/4885GAA 1426/4885 |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | MAPT 3636/4885ALDH1A1 4227/4885GAA 3009/4885 |
| US-11040978-B2 | Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof | MKNK2, MKNK1, MAPKAPK2 | MAPT 430/4885ALDH1A1 3916/4885GAA 2392/4885 |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | MAPT 3514/4885ALDH1A1 404/4885GAA 1687/4885 |
| US-20150231135-A1 | FAK INHIBITORS | PTK2, CTTN, SRC | MAPT 2447/4885ALDH1A1 2762/4885GAA 4640/4885 |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | AIFM2, FECH, GPX4 | MAPT 4384/4885ALDH1A1 395/4885GAA 4193/4885 |
| US-20140371199-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, MKNK2, MAP4K2 | MAPT 525/4885ALDH1A1 4308/4885GAA 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.